The Quality and Reliability of Information in the Summaries of Product Characteristics

Ewelina Drelich, Urszula Religioni, Kevin Chung, Justyna Kaźmierczak, Eliza Blicharska, Agnieszka Neumann-Podczaska, Jerzy Krysiński and Piotr Merks
Additional contact information
Ewelina Drelich: Department of Pharmaceutical Technology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, 85-067 Bydgoszcz, Poland
Urszula Religioni: School of Public Health, Centre of Postgraduate Medical Education of Warsaw, 01-826 Warsaw, Poland
Kevin Chung: Children’s Hospital of Eastern Ontario, Ottawa, ON K1H 8L1, Canada
Justyna Kaźmierczak: Zdrowit sp. z o.o., Pharmacy Chain, ul. Diamentowa 3, 41-940 Piekary Śląskie, Poland
Eliza Blicharska: Department of Analytical Chemistry, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland
Agnieszka Neumann-Podczaska: Chair and Department of Palliative Medicine, Poznan University of Medical Sciences, 61-245 Poznan, Poland
Jerzy Krysiński: Department of Pharmaceutical Technology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, 85-067 Bydgoszcz, Poland
Piotr Merks: Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University in Warsaw, 01-938 Warsaw, Poland

IJERPH, 2022, vol. 19, issue 4, 1-6

Abstract: The Summary of Product Characteristics (SmPC) is an obligatory document concerning a medicine required (among other things) for the authorization of a medicinal product. The purpose of the SmPC is to provide product information to healthcare professionals. A necessary condition for this is to ensure that the SmPC is clear and precise. However, neither European nor national legislation obliges marketing authorization holders to review the SmPC in terms of its readability and understandability prior to the registration of a medicine. To date, research on SmPCs has focused on accuracy and completeness; however, the literature lacks information on the extent to which SmPCs meet the needs of healthcare professionals concerning the readability of the information they contain. The main objective of this article is to point out the lack of precision in the legal provisions for the preparation of SmPCs concerning the comprehensibility of the provisions. The article points to the lack of testing of the SmPC in terms of accessibility and transparency for healthcare professionals, highlighting that the document does not meet the needs of healthcare professionals in providing adequate information about medicines. It shows that the current rules and guidelines for the preparation of the registration dossier for a medicinal product are not entirely precise and contain numerous shortcomings.

Keywords: SmPC; medicinal product; patient safety; medication handling (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/4/2185/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/4/2185/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:4:p:2185-:d:749830

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().